SDGR

Schrödinger's stock price has been influenced by several events in the past six months (April 2026 - October 2026). The company reported strong first-quarter and second-quarter 2026 financial results, with shares rising on October 9, 2026, after exceeding quarterly expectations with $0.08 EPS and $58.89 million in revenue. Strategic collaborations include an agreement with Bristol Myers Squibb to deploy Bunsen in August 2026, a licensing and collaboration agreement with Tectora Therapeutics in September 2026 which led to a 7.6% surge in shares, and a partnership with Eli Lilly in January 2026 to integrate TuneLab into LiveDesign. Inducement grants were reported on April 17, August 14, and September 17, 2026. Analyst ratings changed, with Zacks Research upgrading to 'strong-buy,' Weiss Ratings raising from 'sell (e+)' to 'sell (d-),' UBS Group initiating with 'neutral,' and Wall Street Zen upgrading to 'hold.' Insider trading involved Karen Akinsanya selling 31,599 shares for over $928,000 on September 17, 2026. The stock gained 32.1% over the past 12 months as of October 9, 2026, and reached a new 52-week high of $33.09 on October 6, 2026.